Company performance
Add to research
Current Price
as of Mar 12, 2025$5.11
P/E Ratio
N/A
Market Cap
$23.37M
Loading...
Description
Add to research
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Metrics
Add to research
Overview
- HQStamford, CT
- SectorHealth Technology
- IndustryBiotechnology
- TickerCARA
- Price$5.11-0.29%
Trading Information
- Market cap$23.37M
- Float83.57%
- Average Daily Volume (1m)14,908
- Average Daily Volume (3m)1,186,475
- EPS-$20.99
Company
- Revenue$8.69M
- Rev growth (1yr)-47.47%
- Net income-$12.48M
- Gross margin97.14%
- EBITDA margin-243.66%
- EBITDA-$6.23M
- EV$17.36M
- EV/Revenue2.00
- P/EN/A
- P/S2.69
- P/B33.03
- Debt/Equity6,223.48
Documents
Add to research
SEC Filings
Factset Street Account